Drug Profile
Orgotein
Alternative Names: Artrolasi; Copper zinc SOD; Cu/Zn-superoxide dismutase; Interceptor; Ontosein; Orgo-M; Ormetein; Peroxinorm; Serosod; Superoxide dismutase - GT BiopharmaLatest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator OXIS International
- Developer Tedec Meiji
- Class Anti-inflammatories; Antirheumatics; Metalloproteins; Radioprotectives
- Mechanism of Action Superoxide dismutase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Cystitis; Radiation injuries; Rheumatic disorders
- Discontinued Reperfusion injury
Most Recent Events
- 07 Aug 2017 Oxis International is now called GT Biopharma
- 31 Mar 2011 Orgotein is available for licensing as of 31 Mar 2011. www.oxis.com
- 22 Mar 2004 OXIS International has been acquired by Axonyx